The estimated Net Worth of Michael Maurice Feldman Jes... is at least $90.7 Milion dollars as of 11 March 2015. Michael Jes owns over 6,250,000 units of Champions Oncology Inc stock worth over $90,683,833 and over the last 10 years Michael sold CSBR stock worth over $0.
Michael has made over 1 trades of the Champions Oncology Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Michael bought 6,250,000 units of CSBR stock worth $2,500,000 on 11 March 2015.
The largest trade Michael's ever made was buying 6,250,000 units of Champions Oncology Inc stock on 11 March 2015 worth over $2,500,000. On average, Michael trades about 6,250,000 units every 0 days since 2015. As of 11 March 2015 Michael still owns at least 22,281,040 units of Champions Oncology Inc stock.
You can see the complete history of Michael Jes stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is ONE MARINA PARK DRIVE, SUITE 1100ONE MARINA PARK DRIVE, SUITE 1100, , BOSTONBOSTON, MAMA, 0221002210.
Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown a Sports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Champions Oncology Inc executives and other stock owners filed with the SEC include: